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1 Introduction
The human blood cell production system usually remains extremely robust, in
terms of cell number or function, with little signs of decline in old age. To achieve
robustness, circulating blood cells rely on a formidable production machinery, the
hematopoietic system, located in the bone marrow. All circulating blood cells|
red blood cells, white blood cells and platelets|are renewed on a daily basis.
The hematopoietic system produces an estimated 1012 cells per day. This is a
signicant fraction of the 3:7 1013 cells in an adult [5, 1].
Robustness is partly due to the short time scales at which cell populations are
able to return to equilibrium, combined with large cell numbers and renewal rates.
White blood cells (WBCs), among which neutrophils are most prevalent, are the
body's rst line, innate immune system. Upon infection, WBCs are mobilized from
the bone marrow, to increase their number in circulation and ght o pathogen
within hours [3].
The 26 billion circulating neutrophils in human have a mean residence time of
only 11h in the blood [2]. After their release from the bone marrow, they quickly
disappear in the peripheral tissues and are destroyed in the spleen, liver and bone
marrow [3]. In addition to the high renewal rate of circulating blood cells, a large
number of mature neutrophils, ten times or more the circulating number, is kept
in a bone marrow reserve, ready for entering circulation.
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This high renewal rate and mobilization capability, however, come at a cost.
The blood system is an easy target for chemotherapeutic drugs, whose main way
of acting is by killing proliferating cells. White blood cells and end especially
neutrophils, with their fast turnover, are particularly vulnerable to chemotherapy.
Chemotherapy can induce neutropenia|a state of low absolute neutrophil count
(ANC)|in cancer patients, which puts them at risk of infection.
Homeostatic regulation of white blood cells is mainly controlled by the cy-
tokine Granulocye-Colony Stimulating Factor (G-CSF). G-CSF promotes survival
of white blood cell precursors and their dierentiation into mature cells. The iden-
tication of this protein in the 1980's [7], and the subsequent development of human
recombinant forms of G-CSF paved the way to the treatment of chemotherapy-
induced neutropenia. G-CSF therapy as also been successful at treating congenital
and other forms of neutropenia.
Today, G-CSF is used as an adjuvant in several anti-cancer treatment proto-
cols. The aim of the adjuvant therapy is to minimize the length of the neutropenic
episodes. However, exogenous G-CSF administration interferes with white blood
cell production regulation. What should be a straightforward eect|administer
G-CSF to cause the ANC to increase|turns to be more complicated than that.
For instance, it was observed that early timing of G-CSF administration could
lead to prolonged neutropenic phase [8]. Thus, in order to take advantage of the
full potential of G-CSF, a detailed understanding of the physiological interaction
between neutrophils and exogenous G-CSF is necessary. In this issue of the Bul-
letin, Craig and colleagues present a physiological model of neutrophil production
that includes a detailed modelling of the kinetics of G-CSF.
Mathematical modelling of white blood cell production has a long history [6].
The fundamental structure of all blood cell production models is the delayed nega-
tive feedback loop. The negative feedback loop is the key to a robust homeostasis;
when cell number drops, blood cell production is increased, and cell number quickly
returns to equilibrium. There is an intrinsic delay in the action of the negative loop,
due to the nite time required to produce the extra cells needed. Dysregulation of
parts of the negative feedback loop can lead to oscillation in circulating blood cell
number. An example where this occurs is cyclic neutropenia, a genetic condition
in which the ANC is oscillating with a period of around three weeks in human,
and two weeks in the grey collie. Because the match is so good between clinical
data and model predictions, the feeling is that the dynamics of the hematopoietic
system dynamics is well characterised. This basic view of the negative feedback
loop is too simple, however, if one is interested in short term perturbations of the
hematopoietic system, following rounds of chemotherapy, for instance.
Negative feedback loop-based models of neutrophil production do not incorpo-
rate an explicit action of the G-CSF, and most do not include a mature neutrophil
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pool in the bone marrow. In their model, Craig and colleague have included a
physiological pharmacokinetics/pharmacodynamics (PK/PD) model of G-CSF, in
which they consider the eect of having a pool of bone marrow neutrophils on
G-CSF kinetics, and on the recovery after chemotherapy-induced neutropenia.
It is important to model G-CSF explicitely because exogenous administration
of G-CSF breaks the negative feedback loop: it is possible for the neutrophil count
and the G-CSF concentration to be high at the same time. This mismatch lead
earlier models to underestimate the contribution of neutrophil-mediated G-CSF
clearance.
G-CSF is cleared by two distinct mechanisms, a linear renal clearance and
G-CSF receptors on neutrophils. Bound G-CSF is internalized and subsequently
degraded. After G-CSF administration, rapid bone-marrow neutrophil mobilisa-
tion and disappearance leads to a drop in neutrophil-mediated clearance. Craig
and colleagues show convincing evindence that PK models neglecting the bone
marrow neutrophil reserve overestimate renal clearance and taht neutrophil inter-
nalisation is the main clearance mechanism.
They present a model with ve delay dierential equations (DDEs), three for
the neutrophil dynamics (stem cell number, bone marrow and circulating neu-
trophil count) and two for G-CSF (unbound and bound G-CSF). Mature bone
marrow neutrophil (NR) include a state-dependent time delay NM(t) , which sat-
ises a DDE itself. The time delay accounts for variable neutrophil maturations
speeds. When building a DDE model with varying delays, it is tempting to take
the equations with constant delays and just \add" the time or state-dependence
to the delay terms. This is a mistake, though. The new equations with varying
delays do not represent the intended model, and can lose desirable properties such
positivity of solutions.
To see the diculty with including varying delays, we consider an abstract
regulation model, where the cell population of interest is a pool of mature cells.
We assume that mature cells are produced at a positive rate  dependending
smoothly on the total number of cells x, and representing the rate of new cells
produced after a constant maturation delay  .
A delay dierential equation for x(t) could be written as
dx(t)
dt
= (x(t  ))  x(t); (1)
where  is a death rate. To take into account a time varying delay,   (t), it is
tempting to modify the equation directly and write
dx(t)
dt
= (x(t  (t)))  x(t); (2)
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but this formulation is incorrect. Indeed, if (t) = t, no maturing cell can ever
reach maturity and be released in the mature cell pool, even though the production
rate (x(t  t)) = (x(0)) is non zero.
In order to dene an equation satisifying the modelling assumption that ma-
turing cells spend a varying amount of time in maturation, it is necessary to look
at the underlying transport equation that gives rise to the delay. The simplest
transport equation that gives rise to a varying delay is
@tn(t; a) + v(t)@an(t; a) = 0 (3)
where v(t) is a time varying maturation velocity and a is the maturity level. If cells
are released into the mature pool when they reach a maturity level a = aM , then
the time required for cell to become mature is dened implicitly by the relationship
(t) =
Z t
t (t)
v(s)ds: (4)
From a maturation time viewpoint, equation (3) is a transport equation with a
moving boundary. Dierentiating equation (4) with respect to time yields
1  d(t)
dt
=
v(t)
v(t  (t)) (5)
New mature cells are produced at a rate v(t)n(t; aM ), which is the ux of cell going
trought the boundary a = aM . The analogy of the conveyor belt introduced in [4]
is useful to represent the eect of a varying speed and the boundaries (Fig 1A).
It is convenient to assume v(t)  0, to avoid cells from re-entering the maturation
compartment at a = aM or leaving the compartment at a = 0. In the same way,
the ux of cells entering maturation is v(t)n(t; 0). If we pose that the ux of cell
entering maturation is (x(t), then we have the boundary condition
v(t)n(t; 0) = (x(t)) (6)
Using the characteristics, we have that n(t; aM ) = n(t   (t); 0), and it follows
that
v(t)n(t; aM ) = v(t)n(t  (t); 0) = v(t)
v(t  (t))(x(t  (t))): (7)
Therefore the correct form for the varying time delay equation is
dx(t)
dt
=
v(t)
v(t  (t))(x(t  (t)))  x(t); (8)
together with equation (5). If the form for (t) is known, the time varying delay
equation is
dx(t)
dt
=

1  d(t)
dt

(x(t  (t)))  x(t): (9)
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Figure 1: (A) The conveyor belt analogy [4]. Maturing cells are transported
at speed v(t). The production rate of mature cells is v(t)n(t; aM), while
new cell enter the maturation compartment at a rate (x(t)) = v(t)n(t; 0).
(B) Simulations of equations (9) (solid) and (2) (dashed) with initial history
x() = 1 for  2 [ 0; 0], (x) = k0k2=(k2 + x2), (t) = 0 + A sin(2t=T ),
 = 0:2; k0 = 1:0; k = 1:0; 0 = 10:0; A = 0:5; T = 21.
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Both descriptions valid representations. Equations (5, 8) uses a varying matu-
ration velocity, while equation (9) uses a moving boundary for the length of the
maturation phase. Equation (5) and non-negativity of v(t) imply that d(t)=dt
should never exceed 1. Equation (2) creates cells out of nowhere, leading to slow
build up in cell number even though cell number should stabilise (Fig 1B). Craig
and colleagues took care of keeping the books straight, making sure that all equa-
tions really represent the modelling assumptions.
In total, the full model possesses 32 kinetic parameters, and auxiliary equa-
tions for N , NM , AN , AQ due to non-constant delays, and additional equations for
PK/PD of the chemotherapy. Most of these parameters could be estimated from
the literature, based on a combination of modelling and experimental measure-
ments. The remaining parameters were estimated in a stepwise manner; rst by
characterising parameter constraints at homeostasis, then the G-CSF pharmacoki-
netics parameters and nally the neutrophil dynamics after IV or subcutaneous
G-CSF administration.
Strong feedback mechanisms tend to become unstable, both dynamically and
in terms of parameter sensitivity. To avoid that, Craig and colleagues used a
combination of nonlinear least-square tting together with objective functions that
guaranteed robust ts. This way, Craig and colleagues could characterize not
only physiological neutrophil dynamics, but also the out-of-equilibrium dynamics
following G-CSF administration. A limitation with parameter estimation is the
lack of data about stem cells. They used the obervation that G-CSF administration
speeds up neutrophil precursor transit times to recover some of the stem cells
kinetics.
The last parameter estimation step was made on individual patient chemo-
therapy. Craig and colleagues used neutrophil dynamics data during chemother-
apy to estimate PK parameters. This way, they obtain a full PK/PD model of
neutrophil dynamics during chemotherapy, with a detailed model for G-CSF ad-
ministration.
To check the validity of the model, Craig and colleague simulated the CHOP14
protocol, which includes combined chemotherapy and G-CSF administration. They
compared the simulation of six cycles of 14-day chemotherapy treatment with pub-
lished CHOP14 data. Simulation predictions were very close to the published
data, although no parameters were adjusted. These simulations show how the
administration of G-CSF depletes the bone marrow neutrophil pool, and prevent
circulating neutrophil counts from recovering. These results suggest that delaying
G-CSF administration during chemotherapy would help minimise the severity of
the neutropenia episodes.
This new model for granulopoiesis under exogenous G-CSF treatment illustrate
the need for a realistic description of the physiology when trying to generate clin-
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ically relevant predictions. Including time delays into dierential equation models
has often been made too hastily, leading to modelling errors and raising doubts
about the relevance of such models. This new paper shows how rigorous deriva-
tion of state-dependent time delays can move the boundaries of granulopoiesis
modelling.
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